Trxade Group (MEDS)
(Delayed Data from NSDQ)
$6.90 USD
-0.17 (-2.40%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $6.90 0.00 (0.00%) 7:32 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.90 USD
-0.17 (-2.40%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $6.90 0.00 (0.00%) 7:32 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Eton Pharmaceuticals, Inc. (ETON) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 300% and 84.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 2.28% and 1.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 19.05% and 4.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
DermTech, Inc. (DMTK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -4.21% and 12.11%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
TRxADE (MEDS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
TRxADE (MEDS) delivered earnings and revenue surprises of -50% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 10.77% and 501.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Similar Genomics Systems (OMIC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Similar Genomics Systems (OMIC) delivered earnings and revenue surprises of 2.94% and 39.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
TRxADE (MEDS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
TRxADE (MEDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TRxADE (MEDS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TRxADE (MEDS) delivered earnings and revenue surprises of -66.67% and 8.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About TRxADE (MEDS) Rating Upgrade to Strong Buy
by Zacks Equity Research
TRxADE (MEDS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
TRxADE (MEDS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
TRxADE (MEDS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
All You Need to Know About TRxADE (MEDS) Rating Upgrade to Buy
by Zacks Equity Research
TRxADE (MEDS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TRxADE (MEDS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
TRxADE (MEDS) delivered earnings and revenue surprises of 50% and 27.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
TRxADE (MEDS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TRxADE (MEDS) delivered earnings and revenue surprises of -44.44% and 13.07%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TRxADE (MEDS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TRxADE (MEDS) delivered earnings and revenue surprises of -33.33% and 37.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of 3.33% and 8.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
DermTech, Inc. (DMTK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -18.82% and 1.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: TRxADE (MEDS) Q1 Earnings Expected to Decline
by Zacks Equity Research
TRxADE (MEDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QRTEA vs. MEDS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
QRTEA vs. MEDS: Which Stock Is the Better Value Option?
Company News for Apr 2, 2020
by Zacks Equity Research
Companies In The News Are: CEMI, DPW, MEDS, INSG